Drug class in one race
Tubulin / microtubules drugs for HR+/HER2- Metastatic Breast Cancer
2 tracked Tubulin / microtubules drugs in the HR+/HER2- Metastatic Breast Cancer race. The class explanation lives on the Tubulin / microtubules page; the full indication pipeline across every mechanism is on the HR+/HER2- Metastatic Breast Cancer page.
1 approved / phase 41 Phase 3
Head-to-head evidence: Eribulin mesylate vs Utidelone